BSC
ALNY icon

BOLTON SECURITIES CORPORATION’s Alnylam Pharmaceuticals ALNY Stock Holding History

BOLTON SECURITIES CORPORATION’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.08M Sell
8,427
-17
-0.2% -$4.33K 0.08% 258
2026
Q2 		$2.54M Buy
8,444
+1,250
+17% +$377K 0.09% 229
2026
Q1 		$2.38M Buy
7,194
+6,474
+899% +$2.2M 0.11% 193
2025
Q4 		$286K Buy
720
+79
+12% +$35K 0.01% 680
2025
Q3 		$292K Buy
+641
New +$261K 0.01% 652

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

BOLTON SECURITIES CORPORATION's ALNY Position: Q3 2026 in Review

BOLTON SECURITIES CORPORATION reduced its Alnylam Pharmaceuticals (ALNY) stake by 0.2% in Q3 2026, selling an estimated $4.33K and leaving 8,427 shares worth $2.08M. The position accounts for 0.08% of the portfolio, ranked #258.

BOLTON SECURITIES CORPORATION first reported a position in ALNY in Q3 2025 and has held it in 5 quarters since. The position peaked at $2.54M in Q2 2026. 591 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • BOLTON SECURITIES CORPORATION held 8,427 shares of Alnylam Pharmaceuticals worth $2.08M as of Q3 2026.
  • BOLTON SECURITIES CORPORATION sold 17 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $4.33K.
  • Alnylam Pharmaceuticals made up 0.08% of BOLTON SECURITIES CORPORATION's portfolio in Q3 2026, its #258 holding.
  • BOLTON SECURITIES CORPORATION first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • BOLTON SECURITIES CORPORATION's Alnylam Pharmaceuticals position peaked at $2.54M in Q2 2026.
  • 591 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on BOLTON SECURITIES CORPORATION's 13F filing for Q3 2026, filed 12 Nov 2026.